Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.

Autor: Powles, Thomas, Albiges, Laurence, Jalkanen, Katriina Johanna, De Velasco, Guillermo, Burotto, Mauricio, Ghatalia, Pooja, Suárez, Cristina, Lam, Elaine T., Iacovelli, Roberto, Gumus, Mahmut, Verzoni, Elena, Kollmannsberger, Christian K., Stadler, Walter Michael, Venugopal, Balaji, Shinde, Reshma, Saretsky, Todd L., He, Li, Vickery, Donna, Choueiri, Toni K., Rini, Brian I.
Zdroj: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p361-361, 140p
Databáze: Supplemental Index